Macrogenics INC (MGNX) — 8-K Filings

8-K Filings (13)

• MacroGenics' Tebotelimab Study Meets Primary Endpoint — Apr 8, 2026 Risk: medium
  On April 8, 2026, MacroGenics Inc. filed an 8-K report detailing the results of the Phase 2 LINGO-2 study for its drug tebotelimab. The study met its primary en
• MacroGenics Appoints New Director — Nov 20, 2025 Risk: low
  On November 14, 2025, MacroGenics, Inc. reported a change in its board of directors. Specifically, Dr. Scott R. Vandenberg has been appointed as a Class II Dire
• MacroGenics Files 8-K Report — Aug 14, 2025 Risk: low
  On August 14, 2025, MacroGenics, Inc. filed an 8-K report. The filing primarily serves as a notification of the company's status and does not disclose specific
• MacroGenics Reports Director Changes and Executive Compensation Updates — Aug 13, 2025 Risk: medium
  On August 13, 2025, MacroGenics, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing indica
• MacroGenics Files 8-K: Material Agreement, Other Events — Jun 10, 2025 Risk: medium
  On June 9, 2025, MacroGenics, Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes other events and financial statements
• MacroGenics Files 8-K on Security Holder Vote Matters — May 22, 2025 Risk: low
  On May 21, 2025, MacroGenics, Inc. filed an 8-K report indicating a submission of matters to a vote of security holders. The company, incorporated in Delaware w
• MacroGenics Files 8-K: Board and Executive Compensation Changes — Feb 26, 2025 Risk: medium
  On February 25, 2025, MacroGenics, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing indi
• MacroGenics Appoints New Director — Nov 21, 2024 Risk: low
  On November 18, 2024, MacroGenics, Inc. reported a change in its board of directors. Dr. Scott M. Freeman was appointed as a Class II Director, effective immedi
• MacroGenics Announces CMO Departure and Appointment — Oct 30, 2024 Risk: medium
  On October 25, 2024, MacroGenics, Inc. filed an 8-K report detailing several key events. The company announced the departure of Dr. Scott R. Lippman as Chief Me
• MacroGenics Terminates Henlius Biotech Deal — Sep 16, 2024 Risk: medium
  On September 16, 2024, MacroGenics, Inc. (MGNX) filed an 8-K report to announce the termination of its collaboration and license agreement with Shanghai Henlius
• MacroGenics Appoints New Chief Medical Officer — Jul 30, 2024 Risk: medium
  On July 24, 2024, MacroGenics, Inc. announced the appointment of Dr. Scott R. Vandenberg as its new Chief Medical Officer. Dr. Vandenberg brings extensive exper
• MacroGenics Files 8-K on Shareholder Vote Matters — May 23, 2024 Risk: medium
  On May 21, 2024, MacroGenics, Inc. filed an 8-K report detailing a submission of matters to a vote of security holders. The company, incorporated in Delaware wi
• MacroGenics Files 8-K Report — Apr 3, 2024 Risk: low
  On April 3, 2024, MacroGenics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating update

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX